Denmark-based vaccines company Bavarian Nordic A/S (CPH:BAVA) announced on Wednesday an agreement with vaccine alliance Gavi to secure 500,000 doses of the MVA-BN mpox vaccine (marketed as JYNNEOS or IMVANEX) for Africa.
The vaccines will be funded by Gavi's First Response Fund, a mechanism created after the COVID-19 pandemic to ensure rapid access to scarce vaccine supplies in future health emergencies.
Bavarian Nordic's MVA-BN vaccine received prequalification from the WHO on 13 September. Bavarian Nordic will be ready to supply the vaccines pending the signing of a supply agreement with UNICEF, Gavi's alliance partner, which will be delivering these doses.
Gavi is also working to establish a stockpile of mpox vaccines for future outbreaks and to contribute to the establishment of a sustainable vaccine manufacturing industry in Africa.
Alzinova AB reports positive final Phase 1b results for ALZ-101 in Alzheimer's
Primrose Bio launches Prima RNApols ExTend RNA polymerase for long-template mRNA manufacturing
Merck's CAPVAXIVE approved by EC for pneumococcal disease prevention
Sanofi secures FDA fast track designation for chlamydia vaccine candidate
Anixa Biosciences secures US patent allowance for ovarian cancer vaccine
Valneva to supply IXCHIQ vaccine for chikungunya outbreak in La Réunion
Everest Medicines' EVM14 IND application receives US FDA approval
Clover Biopharmaceuticals' SCB-1019 IND application receives US FDA approval
Centivax partners with Emery Pharma on universal flu vaccine
GSK receives approval from US FDA for Penmenvy 5-in-1 meningitis vaccine
hVIVO secures GBP2m contract for final stage of hMPV characterisation study
EU approves CSL and Arcturus Therapeutics' self-amplifying mRNA COVID-19 vaccine
Sanofi and J&J discontinue phase 3 study of E. coli vaccine candidate
Bain Capital to acquire Mitsubishi Tanabe Pharma in USD3.3bn deal